Presented by: Ken-ichi Tbata MD,PhD
Kitasato University Kitasato Institute Hospital

Introduction

In recent years, various new surgical robot systems have been developed, and Hugo^TM RAS System (Hugo, Medtronic), the third robot following da Vinci and hinotori, was introduced in Japan for the first time in East Asia. The purpose of this study was to evaluate the perioperative outcomes of robotic-assisted radical prostatectomy (RARP) using Hugo in patients with localized prostate cancer.

Materials

We retrospectively analyzed ten consecutive patients who underwent RARP with Hugo from January to March 2023. The patients underwent transperitoneal or extraperitoneal RARP, using five or six trocars (4 robotic trocars and 1 or 2 for the assistant). We reported the clinical feasibility and safety of this new robotic platform, assessing perioperative data, including complications and early outcomes. Continuous variables were reported as median and ranges, categorical variables as proportions.

Results

,

All procedures were safe and feasible with no major compli­cations or conversion. Median console time was 188 minutes (143-222), and median estimated blood loss was 135ml (5-330). Positive surgical margins were reported in 1 patient (11%) in pT2. All patients were hospitalized for 9 days on schedule, and the foley were removed 5 days after RARP. On the first appointment four weeks after surgery, PSA value of all patients were below 0.2 ng/ml.

Conclusion

We demonstrated preliminary perioperative outcome with safe and feasible procedures perfor­med with Hugo^TM RAS System. The surgeries were successfully executed with acceptable outcomes, without major complications. Further investigations with long-term follow-up are awaited to access postoperative functional and oncological outcomes.

Funding

none

Lead Authors

Marie Nkamura, MD
Kitasato University Kitasato Institute Hospital

Daijiro Nishijima, MD
Kitasato University Kitasato Institute Hospital

Masatsugu Iwamura, MD,PHD
Kitasato University